UBS AG Analysts Give Roche Holding Ltd. (ROG) a CHF 260 Price Target
UBS AG set a CHF 260 price target on Roche Holding Ltd. (VTX:ROG) in a research note released on Monday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the healthcare company’s stock.
ROG has been the topic of a number of other reports. HSBC Holdings plc set a CHF 215 target price on Roche Holding and gave the company a sell rating in a report on Tuesday, July 11th. Deutsche Bank AG set a CHF 255 target price on Roche Holding and gave the company a neutral rating in a report on Monday, September 11th. J P Morgan Chase & Co reiterated a buy rating on shares of Roche Holding in a report on Monday. Morgan Stanley set a CHF 260 target price on Roche Holding and gave the company a neutral rating in a report on Friday, October 6th. Finally, BNP Paribas set a CHF 250 target price on Roche Holding and gave the company a neutral rating in a report on Tuesday, June 20th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of Hold and an average target price of CHF 267.73.
Shares of Roche Holding (VTX:ROG) opened at 244.90 on Monday. Roche Holding has a 52 week low of CHK 218.30 and a 52 week high of CHK 273.00. The firm’s 50-day moving average is CHK 244.83 and its 200-day moving average is CHK 251.39. The stock has a market capitalization of CHK 208.96 billion and a price-to-earnings ratio of 21.74.
COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/ubs-ag-analysts-give-roche-holding-ltd-rog-a-chf-260-price-target/1626832.html.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.